A Small Number of Drugs Account for a Large Share of Medicare Part D Spending

The gross Medicare drug spending on the top 10 Part D drugs in 2021 was $48 billion. Eliquis, a blood thinner manufactured by Bristol Myers Squibb, was the top-selling drug, accounting for a quarter of this total, or $12.6 billion (Figure 2). Gross Medicare Part D spending exceeded $5 billion for both Revlimid, a treatment for multiple myeloma also manufactured by Bristol Myers Squibb, and Xarelto, a blood thinner manufactured by Janssen. Five of the 10 top-selling Part D drugs in 2021 are diabetes drugs: Trulicity, Januvia, Jardiance, Lantus Solostar, and Ozempic. You should always check in with out office during AEP (Annual Enrollment Period) each year to make sure you have the right card for you!